# Exagamglogene autotemcel PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/exagamglogene-autotemcel

> The next catalyst for exagamglogene autotemcel, sponsored by VERTEX PHARMACEUTICALS INC / MA (VRTX), is its topline data readout, Jun to Sep 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | exagamglogene autotemcel |
| Codes | CTX001 |
| Sponsor | VERTEX PHARMACEUTICALS INC / MA (VRTX) https://sec-api.dev/companies/vrtx/catalysts |
| Indications | [Sickle Cell Disease](https://sec-api.dev/indications/sickle-cell-disease), [Beta-Thalassemia](https://sec-api.dev/indications/beta-thalassemia) |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### October 31, 2023: FDA advisory committee meeting

- Status: completed. Date confidence: exact.
- First seen 2026-11-12T16:14:42.062Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "On October 31, 2023, the committee will discuss and make recommendations on biologics license application (BLA) 125787 from Vertex Pharmaceuticals, Inc. for exagamglogene autotemcel (exa-cel)." https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-october-31-2023-meeting-announcement-10312023

### November 13, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2/3. Indication: Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03655678 (A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT03655678

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Sickle Cell Disease; Hydroxyurea Failure; Hydroxyurea Intolerance.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05329649 (Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT05329649

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Beta-Thalassemia; Thalassemia; Hematologic Diseases.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05477563 (Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-09 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT05477563

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Sickle Cell Disease; Hydroxyurea Failure; Hydroxyurea Intolerance.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05329649 (Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-06 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT05329649

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Beta-Thalassemia; Thalassemia; Hematologic Diseases.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05477563 (Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-09 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT05477563

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05356195 (Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-14 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT05356195

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05356195 (Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-14 (ESTIMATED); Lead Sponsor Vertex Pharmaceuticals Incorporated." https://clinicaltrials.gov/study/NCT05356195

## Same indication

- [Crizanlizumab](https://sec-api.dev/pdufa/crizanlizumab) (NVS)
- [Etavopivat](https://sec-api.dev/pdufa/etavopivat) (NVO)
- [Exa-cel](https://sec-api.dev/pdufa/exa-cel) (VRTX)
- [Inclacumab](https://sec-api.dev/pdufa/inclacumab) (PFE)
- [Ndec - oral decitabine-tetrahydrouridine](https://sec-api.dev/pdufa/ndec-oral-decitabine-tetrahydrouridine) (NVO)
- [PCV21](https://sec-api.dev/pdufa/pcv21) (SNY)
- [Pociredir](https://sec-api.dev/pdufa/pociredir) (FULC)
- [Wayrilz (rilzabrutinib)](https://sec-api.dev/pdufa/rilzabrutinib) (SNY)
- [Tebapivat](https://sec-api.dev/pdufa/tebapivat) (AGIO)

Calendar months: [June 2027](https://sec-api.dev/fda-calendar/2027-06), [November 2027](https://sec-api.dev/fda-calendar/2027-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/exagamglogene-autotemcel.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Exagamglogene autotemcel PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/exagamglogene-autotemcel

```bibtex
@misc{secapidev_pdufa_exagamglogene_autotemcel_20261116,
  title        = {Exagamglogene autotemcel PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/exagamglogene-autotemcel}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_exagamglogene_autotemcel_20261116","title":"Exagamglogene autotemcel PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/exagamglogene-autotemcel","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
